Advanced search
Publication Cover
International Journal of Chronic Obstructive Pulmonary Disease Volume 15, 2020 - Issue
Submit an article Journal homepage
107
Views
2
CrossRef citations to date
0
Altmetric
Original Research

Glycopyrrolate/Formoterol Fumarate Metered Dose Inhaler Improves Lung Function versus Monotherapies in GOLD Category A Patients with COPD: Pooled Data from the Phase III PINNACLE Studies

Fernando J Martinez1 Joan and Sanford I. Weill Department of Medicine, Weill Cornell Medicine, New York, NY, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0002-2412-3182
ORCID Icon,
Klaus F Rabe2 Department of Pneumonology, LungenClinic Grosshansdorf and Christian-Albrechts University Kiel, Airway Research Center North, Member of the German Center for Lung Research (DZL), Grosshansdorf, Germany
,
Brian J Lipworth3 Division of Molecular and Clinical Medicine, Scottish Centre for Respiratory Research, Ninewells Hospital, University of Dundee, Dundee, Scotland, UKORCID Iconhttps://orcid.org/0000-0002-8140-2014
ORCID Icon,
Samir Arora4 Aventiv Research Inc., Columbus, OH, USA
,
Martin Jenkins5 Global Medicines Development, AstraZeneca, Cambridge, UK
,
Ubaldo J Martin6 Research and Development, AstraZeneca, Gaithersburg, MD, USAORCID Iconhttps://orcid.org/0000-0002-0089-7677
ORCID Icon &
Colin Reisner6 Research and Development, AstraZeneca, Gaithersburg, MD, USA;7 R&D Biopharmaceuticals, AstraZeneca, Morristown, NJ, USAORCID Iconhttps://orcid.org/0000-0003-1856-9863
ORCID Icon show all
Pages 99-106 | Published online: 09 Jan 2020

References

  • Global Initiative for Chronic Obstructive Lung Disease. 2011 report: Global Strategy for the Diagnosis, Management and Prevention of COPD; 2011 Available from: https://goldcopd.org. Accessed June 28, 2019.
  • Global Initiative for Chronic Obstructive Lung Disease. 2020 report: Global Strategy for the Diagnosis, Management and Prevention of COPD; 2020 Available from: https://goldcopd.org. Accessed 115, 2019.
  • GlaxoSmithKline. COPD Assessment Test; 2009 Available from: http://www.catestonline.org/. Accessed 628, 2019.
  • MahlerDA, WellsCK. Evaluation of clinical methods for rating dyspnea. Chest. 1988;93(3):580–586. doi:10.1378/chest.93.3.5803342669
  • MahlerDA, KerwinE, AyersT, et al. FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/glycopyrrolate) versus its monocomponents and placebo in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2015;192(9):1068–1079. doi:10.1164/rccm.201505-1048OC26177074
  • DonohueJF, Maleki-YazdiMR, KilbrideS, MehtaR, KalbergC, ChurchA. Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in COPD. Respir Med. 2013;107(10):1538–1546. doi:10.1016/j.rmed.2013.06.00123830094
  • DecramerM, AnzuetoA, KerwinE, et al. Efficacy and safety of umeclidinium plus vilanterol versus tiotropium, vilanterol, or umeclidinium monotherapies over 24 weeks in patients with chronic obstructive pulmonary disease: results from two multicentre, blinded, randomised controlled trials. Lancet Respir Med. 2014;2(6):472–486. doi:10.1016/S2213-2600(14)70065-724835833
  • CelliB, CraterG, KilbrideS, et al. Once-daily umeclidinium/vilanterol 125/25 mcg therapy in COPD: a randomized, controlled study. Chest. 2014;145(5):981–991. doi:10.1378/chest.13-157924385182
  • MartinezFJ, RabeKF, FergusonGT, et al. Efficacy and safety of glycopyrrolate/formoterol metered dose inhaler formulated using co-suspension delivery technology in patients with COPD. Chest. 2017;151(2):340–357. doi:10.1016/j.chest.2016.11.02827916620
  • HananiaNA, TashkinDP, KerwinEM, et al. Long-term safety and efficacy of glycopyrrolate/formoterol metered dose inhaler using novel Co-Suspension™ Delivery Technology in patients with chronic obstructive pulmonary disease. Respir Med. 2017;126:105–115. doi:10.1016/j.rmed.2017.03.01528427541
  • LipworthBJ, CollierDJ, GonY, et al. Improved lung function and patient-reported outcomes with co-suspension delivery technology glycopyrrolate/formoterol fumarate metered dose inhaler in COPD: a randomized Phase III study conducted in Asia, Europe, and the USA. Int J Chron Obstruct Pulmon Dis. 2018;13:2969–2984. doi:10.2147/COPD.S17183530310273
  • Global Initiative for Chronic Obstructive Lung Disease. 2017 report: Global Strategy for the Diagnosis, Management and Prevention of COPD; 2017 Available from: https://goldcopd.org/archived-reports/. Accessed 628, 2019.
  • CelliBR, MacNeeW, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932–946. doi:10.1183/09031936.04.0001430415219010
  • DonohueJF. Minimal clinically important differences in COPD lung function. COPD. 2005;2(1):111–124. doi:10.1081/COPD-20005337717136971
  • MartinezFJ, FabbriLM, FergusonGT, et al. Baseline symptom score impact on benefits of glycopyrrolate/formoterol metered dose inhaler in COPD. Chest. 2017;152(6):1169–1178. doi:10.1016/j.chest.2017.07.00728720336
  • SinghD, GagaM, SchmidtO, et al. Effects of tiotropium + olodaterol versus tiotropium or placebo by COPD disease severity and previous treatment history in the OTEMTO® studies. Respir Res. 2016;17(1):73. doi:10.1186/s12931-016-0387-727316465
  • BattistiWP, WagerE, BaltzerL, et al. Good publication practice for communicating company-sponsored medical research: GPP3. Ann Intern Med. 2015;163(6):461–464. doi:10.7326/M15-028826259067
  • MartinezFJ, RabeKF, LipworthBJ, et al. Glycopyrrolate/formoterol fumarate metered dose inhaler (GFF MDI) improves lung function in GOLD category A patients with COPD: pooled data from the Phase III PINNACLE studies. Am J Respir Crit Care Med. 2019;199:A3345.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.